Short answer
Praxis Precision Medicines, Inc. (PRAX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$74M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$74M
- −42.4% YoY · −3.9% QoQ
- EPS (diluted)
- −$3.37
- −20.4% YoY · −1.8% QoQ
Source: XBRL data from the Praxis Precision Medicines, Inc. (PRAX) Q3 2025 10-Q on SEC EDGAR. USD.
Praxis Precision Medicines, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new or changed risk factors compared to 10-K filed February 28, 2025
- Clinical trial outcomes and regulatory approval remain key risks for near-term operational performance
- Regulatory risk centered on FDA approval processes for pipeline drugs, as previously disclosed
- Commercialization competition in precision medicines impacts market positioning and revenue growth
- Financial risk from limited cash runway and dependence on milestone-based funding continues unchanged
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Praxis Precision Medicines, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.